Literature DB >> 8904442

Immune response to hepatitis A virus capsid proteins after infection.

C H Wang1, S Y Tschen, U Heinricy, M Weber, B Flehmig.   

Abstract

This study was undertaken to determine the immune response of humans to viral capsid polypeptides of hepatitis A virus (HAV) after natural infection, which is very important for vaccine development. Antiviral capsids in 73 serum samples from patients with acute and chronic HAV infections were analyzed by immunoblotting against individual HAV capsid polypeptides (VP1, VP2, VP3, and VP4) by using a cell culture-based HAV antigen. For reference, total anti-HAV immunoglobulin G (IgG) and anti-HAV IgM were also determined by radioimmunoassay. As a result, a dominant immune response against VP1 (98% IgG, 94% IgM) was found in the acute phase. However, many other sera also reacted with VP0 (88% IgG; 35% IgM) and VP3 (81% IgG and 29% IgM). In contrast to the acute phase, anti-VP1, anti-VP0, and anti-VP3, IgG antibodies against all three viral proteins (29, 29, and 73% respectively), especially those against VP3, were found years after onset of HAV disease and over long periods in the sera of hepatitis patients. These results suggest that antibodies for capsid polypeptides are present over an extended period in the sera of HAV-infected patients. They are likely of importance in maintaining long-term immunity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904442      PMCID: PMC228874          DOI: 10.1128/jcm.34.3.707-713.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Properties of a hepatitis A virus candidate vaccine strain.

Authors:  U Heinricy; Y D Stierhof; M Pfisterer; B Flehmig
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

Review 2.  Hepatitis A virus: insights from molecular biology.

Authors:  J I Cohen
Journal:  Hepatology       Date:  1989-06       Impact factor: 17.425

3.  Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers.

Authors:  B Flehmig; U Heinricy; M Pfisterer
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

4.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus.

Authors:  L H Ping; R W Jansen; J T Stapleton; J I Cohen; S M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Regulation of the human immune response to HBsAg: effects of antibodies and antigen conformation in the stimulation of helper T cells by HBsAg.

Authors:  E Celis; I Kato; R W Miller; T W Chang
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

7.  A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus.

Authors:  B Flehmig; M Ranke; H Berthold; H J Gerth
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

8.  Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay.

Authors:  D W Bradley; J E Maynard; S H Hindman; C L Hornbeck; H A Fields; K A McCaustland; E H Cook
Journal:  J Clin Microbiol       Date:  1977-05       Impact factor: 5.948

9.  Immunoreactivity of human and rabbit antisera to hepatitis A virus.

Authors:  V Gauss-Müller; F Deinhardt
Journal:  J Med Virol       Date:  1988-02       Impact factor: 2.327

10.  Isolation and immunizations with hepatitis A viral structural proteins: induction of antiprotein, antiviral, and neutralizing responses.

Authors:  J V Hughes; L W Stanton
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

View more
  7 in total

Review 1.  Diagnosis of hepatitis a virus infection: a molecular approach.

Authors:  Omana V Nainan; Guoliang Xia; Gilberto Vaughan; Harold S Margolis
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 2.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

Review 3.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

Review 4.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

5.  Rapid Salivary IgG Antibody Screening for Hepatitis A.

Authors:  Swinburne A J Augustine; Tarsha N Eason; Kaneatra J Simmons; Shannon M Griffin; Clarissa L Curioso; Malini K D Ramudit; Elizabeth A Sams; Kevin H Oshima; Alfred Dufour; Timothy J Wade
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

6.  Tissue-specific abundance of regulatory T cells correlates with CD8+ T cell dysfunction and chronic retrovirus loads.

Authors:  Lara Myers; Ronald J Messer; Aaron B Carmody; Kim J Hasenkrug
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

7.  Evidence of Circulation of Several HAV Genetic Variants and Emergence of Potential Antigenic Variants in an Endemo-Epidemic Country before Vaccine Introduction.

Authors:  Kaouther Ayouni; Anissa Chouikha; Oussema Khamessi; Henda Touzi; Walid Hammemi; Henda Triki
Journal:  Viruses       Date:  2021-06-03       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.